Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
Status:
Terminated
Trial end date:
2022-10-26
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical
study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and
immunogenicity of IMM01 in subjects with refractory or recurrent hematologic malignancy.